FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway
Cell Biology and Toxicology · 2024
DOI: 10.1007/s10565-024-09899-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology and Toxicology, 2024. Verfasst von Jianfa Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Forkhead Transcription Factors, Kidney Neoplasms, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Increased activity of the transcription factor FOXC1 leads to elevated transcription of target genes, ultimately facilitating the progression of various cancer types. However, there are currently no literature reports on the role of FOXC1 in renal cell carcinoma.
Methods
By using RT-qPCR, immunohistochemistry and Western blotting, FOXC1 mRNA and protein expression was evaluated. Gain of function experiments were utilized to assess the proliferation and metastasis ability of cells. A nude mouse model was created for transplanting tumors and establishing a lung metastasis model to observe cell proliferation and spread in a living organism. Various techniques including biological analysis, CHIP assay, luciferase assay, RT-qRCR and Western blotting experiments were utilized to investigate how FOXC1 contributes to the transcription of ABHD5 on a molecular level. FOXC1 was assessed by Western blot for its impact on AMPK/mTOR signaling pathway.
Results
FOXC1 is down-regulated in RCC, causing unfavorable prognosis of patients with RCC. Further experiments showed that forced FOXC1 expression significantly restrains RCC cell growth and cell metastasis. Mechanically, FOXC1 promotes the transcription of ABHD5 to activate AMPK signal pathway to inhibit mTOR signal pathway. Finally, knockdown of ABHD5 recovered the inhibitory role of FOXC1 overexpression induced cell growth and metastasis suppression.
Conclusion
In general, our study demonstrates that FOXC1 exerts its tumor suppressor role by promoting ABHD5 transcription to regulating AMPK/mTOR signal pathway. FOXC1 could serve as both a diagnostic indicator and potential treatment focus for RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology, Peking University First Hospital, Beijing, China.
- Department of Urology, Peking University First Hospital, Beijing, China. huangchenchen77@163.com.
- Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China. shuge2020@outlook.com.
Zitieren
APA
Li, J., Chen, S., Xiao, J., Ji, J., Huang, C., & Shu, G. (2024). FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-024-09899-w
Vancouver
Li J, Chen S, Xiao J, Ji J, Huang C, Shu G. FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway. Cell Biology and Toxicology. 2024. doi:10.1007/s10565-024-09899-w
BibTeX
@article{Li2024,
author = {Li, Jianfa and Chen, Shuangchen and Xiao, Jing and Ji, Jiayuan and Huang, Chenchen and Shu, Ge},
title = {FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway},
journal = {Cell Biology and Toxicology},
year = {2024},
doi = {10.1007/s10565-024-09899-w}
}
EUVIMED